Furthermore, as KD-fed Creb3l3−/− mice exhibited severe fatty liver, activating inflammation, CREB3L3 could be a therapeutic target for NAFLD. Here, CREB3L3 is linked to metabolic dysfunction-associated steatotic liver disease.